Monthly information on share capital and company voting rights

Rhea-AI Summary

Cellectis announced its total number of shares as of November 30, 2022, standing at 45,579,410, with total voting rights totaling 51,646,286.

Cellectis, listed on both Nasdaq Global Market (ticker: CLLS) and Euronext Growth (ticker: ALCLS), focuses on gene-editing therapies targeting cancers and blood disorders. Its proprietary technologies include TALEN® and PulseAgile.

The company aims to address unmet medical needs through innovative cell and gene therapies, notably for acute myeloid leukemia and multiple myeloma.

Positive

• Cellectis has a total of 45,579,410 shares outstanding, which can indicate strong equity based on its capital structure.
• The company is focused on developing cutting-edge therapies for cancers and blood disorders, showing a commitment to addressing unmet medical needs.

Negative

• None.

(Article 223-16 of General Regulation of the French financial markets authority)

NEW YORK, Dec. 16, 2022 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

Date	Total number of shares in the capital	Total number of voting rights
11/30/2022	45,579,410	51,646,286

About Cellectis
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 22 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing lifesaving UCART product candidates for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM). .HEAL is a new platform focusing on hemopoietic stem cells to treat blood disorders, immunodeficiencies and lysosomal storage diseases.

Cellectis’ headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina.

Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).

For more information, visit www.cellectis.com
Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.

For further information, please contact:

Media contacts:
Pascalyne Wilson, Director, Communications, +33776991433, media@cellectis.com
Margaret Gandolfo, Senior Manager, Communications, +1 (646) 628 0300

Investor Relation contact:
Arthur Stril, Chief Business Officer, +1 (347) 809 5980, investors@cellectis.com
Ashley R. Robinson, LifeSci Advisors, +1 (617) 430 7577 

Attachment

• Voting_Rights_PR_nov_EN.pdf

FAQ

What is the total number of shares for Cellectis as of November 30, 2022?

Cellectis had a total of 45,579,410 shares outstanding as of November 30, 2022.

What are the voting rights for Cellectis?

As of November 30, 2022, Cellectis had total voting rights of 51,646,286.

What is the ticker symbol for Cellectis on Nasdaq?

Cellectis is listed on Nasdaq under the ticker symbol CLLS.

Where is Cellectis headquartered?

Cellectis is headquartered in Paris, France, with locations in New York and Raleigh.

What technologies does Cellectis use for gene editing?

Cellectis utilizes TALEN® and PulseAgile technologies for its gene editing and therapy development.